Tom Kean, the Republican congressman from New Jersey, finally addressed speculation surrounding his unexpected 117‑day hiatus from Capitol Hill. After weeks of silence, the lawmaker said a depressive episode forced him to step away from duties and seek treatment. His disclosure ends a period of uncertainty that kept constituents and markets guessing about the district’s representation to his colleagues and staff.

Stakeholders in Washington watched the episode closely because prolonged absences can shift committee assignments and affect legislative momentum. Kean’s seat commands a modest but reliable fundraising base, and his absence raised concerns among donors about future campaign cash flow. By confirming a medical cause, the congressman aims to reassure investors and local businesses that his office will resume normal operations in the near term.

While the health disclosure carries no immediate policy shift, it underscores the personal risks that can interrupt representation for swing districts. Analysts note that Kean’s return is likely to restore his voting record and committee influence, preserving the GOP’s narrow edge in the House. The congressman’s statement therefore removes a lingering uncertainty from New Jersey’s political calculus.